Systemic Aspergillosis And Systemic Candidasis Market Scope And Analysis

Report Code : TIPRE00016906
Category : Life Sciences

No. of Pages : 150

Buy Now

Systemic Aspergillosis and Systemic Candidasis Market Scope and Analysis Report by 2031

Buy Now

Systemic Aspergillosis and Systemic Candidasis Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 6.73 Billion
Market Size by 2031	US$ 10.03 Billion
Global CAGR (2023 - 2031)	4.1%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Type Voriconazole Liposomal Amphotericin B Systemic Oral Azoles Topical Antifungal Agents By Application Chronic Pulmonary Aspergillosis Allergic Bronchopulmonary Aspergillosis Gastrointestinal Candidiasis Genitourinary Tract Candidiasis
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Novartis AG Sanofi Aventis Pfizer Inc Merck and Co Inc Enzon Pharmaceuticals Inc Bayer AG Astellas Pharma Inc GlaxoSmithKline plc Abbott Cipla

Systemic Aspergillosis and Systemic Candidasis Market News and Recent Developments

The Systemic Aspergillosis and Systemic Candidasis Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for systemic aspergillosis and systemic candidasis and strategies:

Pfizer acquired Amplyx Pharmaceuticals, Inc. Pfizer has secured ownership of Amplyx's early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies. (Source: Pfizer, Press Release, 2021)
Basilea Pharmaceutica Ltd has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., acquired the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. In addition, Basilea has acquired the rights to a preclinical antifungal compound. (Source: Biospace, Press Release, 2023)

Systemic Aspergillosis and Systemic Candidasis Market Report Coverage and Deliverables

The “Systemic Aspergillosis and Systemic Candidasis Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles